Basic Information
Memantine Mylan
Regulatory Information
EMEA/H/C/002660
Authorised
April 21, 2013
13
February 20, 2025
Company Information
Ireland
Damastown Industrial Park Mulhuddart Dublin 15
MYLAN PHARMACEUTICALS PRIVATE LIMITED
Drug Classification
Generic Medicine
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of patients with moderate to severe Alzheimer’s disease.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Memantine Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Memantine Mylan. For practical information about using Memantine Mylan, patients should read the package leaflet or contact their doctor or pharmacist.